Exact Sciences logo

EXAS - Exact Sciences Share Price

$130.04 -0.5  -0.4%

Last Trade - 9:00pm

Large Cap
Market Cap £16.01bn
Enterprise Value £15.85bn
Revenue £1.08bn
Position in Universe 541st / 6851
Unlock EXAS Revenue
Relative Strength (%)
1m -3.73%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -18.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
39.4 99.4 266 454.5 876.3 1,491 1,732 2,157 +106.8%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, EXACTSciences Corporation revenues increased 70% to $1.49B. Netloss increased from $84M to $848.5M. Revenues reflectUnited States (Country) segment increase of 63% to $1.41B,Outside of united states segment increase from $11.4M to$77.5M. Higher net loss reflects Personnel Expensesincrease of 68% to $280.3M (expense), Personnel Expensesincrease of 63% to $222M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for EXAS
Graphical History


EXAS Revenue Unlock EXAS Revenue

Net Income

EXAS Net Income Unlock EXAS Revenue

Normalised EPS

EXAS Normalised EPS Unlock EXAS Revenue

PE Ratio Range

EXAS PE Ratio Range Unlock EXAS Revenue

Dividend Yield Range

EXAS Dividend Yield Range Unlock EXAS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
EXAS EPS Forecasts Unlock EXAS Revenue
Profile Summary

Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated February 10, 1995
Public Since January 30, 2001
No. of Shareholders: 336
No. of Employees: 4,800
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 169,093,162
Free Float (0.0%)
Eligible for
EXAS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for EXAS
Upcoming Events for EXAS
Tuesday 4th May, 2021
Q1 2021 Exact Sciences Corp Earnings Release
Tuesday 4th May, 2021
Q1 2021 Exact Sciences Corp Earnings Call
Friday 23rd July, 2021 Estimate
Exact Sciences Corp Annual Shareholders Meeting
Wednesday 28th July, 2021 Estimate
Q2 2021 Exact Sciences Corp Earnings Release
Frequently Asked Questions for Exact Sciences
What is the Exact Sciences share price?

As of 9:00pm, shares in Exact Sciences are trading at $130.04, giving the company a market capitalisation of £16.01bn. This share price information is delayed by 15 minutes.

How has the Exact Sciences share price performed this year?

Shares in Exact Sciences are currently trading at $130.04 and the price has moved by 95.33% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Exact Sciences price has moved by 32.58% over the past year.

What are the analyst and broker recommendations for Exact Sciences?

Of the analysts with advisory recommendations for Exact Sciences, there are there are currently 9 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Exact Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Exact Sciences next release its financial results?

Exact Sciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Exact Sciences dividend yield?

Exact Sciences does not currently pay a dividend.

Does Exact Sciences pay a dividend?

Exact Sciences does not currently pay a dividend.

When does Exact Sciences next pay dividends?

Exact Sciences does not currently pay a dividend.

How do I buy Exact Sciences shares?

To buy shares in Exact Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Exact Sciences?

Shares in Exact Sciences are currently trading at $130.04, giving the company a market capitalisation of £16.01bn.

Where are Exact Sciences shares listed? Where are Exact Sciences shares listed?

Here are the trading details for Exact Sciences:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: EXAS
What kind of share is Exact Sciences?

Based on an overall assessment of its quality, value and momentum, Exact Sciences is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Exact Sciences share price forecast 2021?

Shares in Exact Sciences are currently priced at $130.04. At that level they are trading at 30.73% discount to the analyst consensus target price of 0.00.

Analysts covering Exact Sciences currently have a consensus Earnings Per Share (EPS) forecast of -3.5 for the next financial year.

How can I tell whether the Exact Sciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exact Sciences. Over the past six months, the relative strength of its shares against the market has been 4.96%. At the current price of $130.04, shares in Exact Sciences are trading at 13.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Exact Sciences PE Ratio?

We were not able to find PE ratio data for Exact Sciences.

Who are the key directors of Exact Sciences?

Exact Sciences's management team is headed by:

Kevin Conroy - CHM
Graham Lidgard - SVP
Thomas Carey - IND
James Doyle - IND
D. Scott Coward - SVP
Jeffrey Elliott - CFO
Ana Hooker - SVP
Scott Johnson - SVP
Pierre Jacquet - IND
Torsten Hoof - GMG
Jake Orville - GMG
Gisela Paulsen - GMG
Shacey Petrovic - DRC
Pat Setji - VOP
Paul Clancy - DRC
Who are the major shareholders of Exact Sciences?

Here are the top five shareholders of Exact Sciences based on the size of their shareholding:

T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 9.79% (16.5m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.4% (14.2m shares)
Capital World Investors Investment Advisor
Percentage owned: 6.09% (10.3m shares)
American Funds Growth Fund of America Mutual Fund
Percentage owned: 3.94% (6.67m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.65% (6.16m shares)
Similar to EXAS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.